New Natera CEO Highlights Three Goals for Company at JP Morgan

Jan 10, 2019

|

SAN FRANCISCO (GenomeWeb) – Natera plans to focus on three main goals in the coming year, according to its new CEO, Steve Chapman: expanding its leadership in reproductive health by pushing toward becoming cash-flow break-even in that business, establishing Signatera as a standard test in cancer care, and commercializing and securing reimbursement coverage for its kidney transplantation test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Breaking News

Featured White Papers

The BD Veritor Plus System

Advancing Patient Care and Aiding Diagnosis at the Point of Care

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

Molecular Tests Provide a Better Alternative to Stool Culture for GI Cases

Mar

21

Featured Webinar

A Long-Read vs. Short-Read Platform Comparison (Part 2): Best NGS Approaches for Human Transcriptome Sequencing

This webinar provides a comparison of next-generation sequencing (NGS) approaches for human transcriptome sequencing, including short-read Illumina sequencing and synthetic long-read sequencing technology.

Mar

26

Featured Webinar

Advancing Agricultural Genomics with Low-Cost NGS Genotyping

This webinar will address the current status and future directions for massively high-throughput genomics for plant and animal breeding and research.

Mar

27

Featured Webinar

How One NGS Core Lab Reduced Sequencing Costs with a Novel Library Normalization Kit

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.

Mar

28

Featured Webinar

The Human Gene Mutation Database: Empowering a Generation of Geneticists for Precision Medicine

The Human Gene Mutation Database (HGMD) is a manually curated, comprehensive collection of disease-causing, germline mutations. Since 1996, a team of experts has manually catalogued over a quarter of a million mutations for the database.

Menu